BiotechTube

Romosozumab + Bisphosphonate

Phase 3Recruiting
0 watching 0 views this week📈 Rising
76
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Osteogenesis Imperfecta

Conditions

Osteogenesis Imperfecta

Trial Timeline

Apr 22, 2024 → Aug 25, 2027

NCT ID
NCT05972551

About Romosozumab + Bisphosphonate

Romosozumab + Bisphosphonate is a phase 3 stage product being developed by Amgen for Osteogenesis Imperfecta. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05972551. Target conditions include Osteogenesis Imperfecta.

Hype Score Breakdown

Clinical
27
Activity
18
Company
9
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT05972551Phase 3Recruiting

Competing Products

16 competing products in Osteogenesis Imperfecta

See all competitors
ProductCompanyStageHype Score
Teriparatide (FORTEO) + PlacebosEli LillyApproved
85
Zoledronic AcidNovartisPhase 2
52
Zoledronic AcidNovartisPhase 2
52
Zoledronic AcidNovartisPhase 3
77
RomosozumabAmgenPhase 1
32
DenosumabAmgenPhase 3
76
Denosumab + Alternative osteoporosis medicationsAmgenPhase 3
76
FresolimumabSanofiPhase 1
32
SAR439459 + PlaceboSanofiPhase 1
32
BPS804Ultragenyx PharmaceuticalPhase 2
47
SetrusumabUltragenyx PharmaceuticalPhase 2/3
60
SetrusumabUltragenyx PharmaceuticalPhase 2
47
BPS804Ultragenyx PharmaceuticalPhase 2
47
setrusumabUltragenyx PharmaceuticalPhase 3
72
setrusumab + zoledronic acid (optional)Ultragenyx PharmaceuticalPhase 2
47
Bisphosphonate + SetrusumabUltragenyx PharmaceuticalPhase 3
72

Other Products from Amgen

Aranesp®Approved
84
PanitumumabApproved
84
EvolocumabApproved
84
Prolia®Approved
84
EvolocumabApproved
84